Neuphoria Therapeutics Inc. - Common Stock, $0.00001 par value per share (NEUP)

Q: What does CUSIP 64136E102 represent in this 13F holders report?

CUSIP 64136E102 is the security identifier for NEUP - Neuphoria Therapeutics Inc. - Common Stock, $0.00001 par value per share used to aggregate holder disclosures.

Q: How many institutions held NEUP - Neuphoria Therapeutics Inc. - Common Stock, $0.00001 par value per share in Q4 2024?

7 institutional investors reported NEUP - Neuphoria Therapeutics Inc. - Common Stock, $0.00001 par value per share for Q4 2024. Use the holders table for investor-level position and value details.

CUSIP: 64136E102

Q4 2024 13F Holders as of 31 Dec 2024

Type / Class: Equity / Common Stock, $0.00001 par value per share
Shares outstanding: 5,420,049
Total 13F shares: 79,719
Share change: +69,692
Total reported value: $273,435
Price per share: $3.43
Number of holders: 7
Value change: +$239,042
Number of buys: 6

Quarterly Holders Quick Answers

What is CUSIP 64136E102?
CUSIP 64136E102 identifies NEUP - Neuphoria Therapeutics Inc. - Common Stock, $0.00001 par value per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q1 2025

Recent filing periods for CUSIP 64136E102:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024

Top shareholders of NEUP - Neuphoria Therapeutics Inc. - Common Stock, $0.00001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
ARMISTICE CAPITAL, LLC	13D/G	—	5%	1,033,796	$5,365,401	$0	31 Dec 2024	13D/G

Institutional Holders of Neuphoria Therapeutics Inc. - Common Stock, $0.00001 par value per share (NEUP) as of Q4 2024

As of 31 Dec 2024, Neuphoria Therapeutics Inc. - Common Stock, $0.00001 par value per share (NEUP) was held by 7 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 79,719 shares. The largest 7 holders included Lynx1 Capital Management LP, JANE STREET GROUP, LLC, Merck & Co., Inc., BANK OF AMERICA CORP /DE/, UBS Group AG, RHUMBLINE ADVISERS, and MORGAN STANLEY. This page lists 7 institutional shareholders reporting positions in this security for the Q4 2024 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2024 vs Q4 2025 Across Filers

Q4 2025 holders

Q4 2024 holders

Holder diff

-14

Investor	Q4 2025 Shares	Q4 2024 Shares	Share Diff	Share Chg %	Q4 2025 Value $	Q4 2024 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.